Teleflex Inc Stock Price, News & Analysis

Teleflex Incorporated's CEO, Liam Kelly, will present at the Wells Fargo 2020 Virtual Healthcare Conference on September 9, 2020, at 12:40 p.m. (ET). A live webcast of his presentation will be accessible on the company's investor section of the website. Teleflex is a global medical technology provider focused on improving healthcare through innovative solutions across various medical fields such as vascular access, cardiology, and respiratory care.

Teleflex (NYSE: TFX) released its 2nd annual Global JOIN Impact Report, detailing progress made in 2019 on corporate social responsibility initiatives focusing on environmental sustainability and community engagement. The report highlights efforts in promoting pollination awareness under the theme ‘Planting with Purpose’. CEO Liam Kelly praised employee dedication to their mission of improving health and quality of life globally. The report is accessible via the company's website.

NeoTract, a subsidiary of Teleflex, has designated Dr. Robert Waguespack as a UroLift® Center of Excellence for his expertise in treating Benign Prostatic Hyperplasia (BPH). The UroLift System offers a minimally invasive solution for BPH, indicated by major urological associations and supported by clinical data showing rapid symptom relief. This procedure is gaining traction as an alternative to traditional medication and surgery, with over 100,000 men treated in the U.S. alone. The UroLift's FDA clearance and positive patient outcomes highlight its role in improving urological health for millions of men.

Teleflex (NYSE: TFX) has declared a quarterly cash dividend of $0.34 per share. This dividend will be paid on September 15, 2020 to shareholders recorded by the close of business on August 14, 2020. As a global provider of medical technologies, Teleflex focuses on innovations that enhance patient care. The company’s diverse portfolio includes solutions in areas like vascular access and anesthesia, reflecting its commitment to meeting clinical needs. For more details, visit teleflex.com.

Teleflex reported second quarter 2020 revenues of $567.0 million, a decline of 13.1% year-over-year, attributed largely to a $130 million revenue hit from COVID-19. GAAP diluted EPS fell 86.4% to $0.24, while adjusted diluted EPS decreased 27.4% to $1.93. The company announced a workforce reduction to improve cost structure and is not reinstating 2020 financial guidance due to ongoing pandemic uncertainties. Despite challenges, Teleflex holds over $550 million in cash and plans to continue generating long-term growth.

Teleflex announced that the UroLift System has successfully treated 200,000 patients suffering from benign prostatic hyperplasia (BPH), a condition affecting over 40 million men in the U.S. The minimally invasive device offers rapid symptom relief with quick recovery, allowing men to return to normal activities while preserving sexual function. The company's president noted the increasing physician adoption and positive real-world data supporting the UroLift's efficacy as a standard treatment for BPH.

Teleflex, ticker TFX, has presented data on the UroLift System for treating benign prostatic hyperplasia (BPH) at the EAU 2020 virtual congress. The studies confirmed the system's safety and effectiveness in diverse patient groups, highlighting significant improvements in the International Prostate Symptom Score (IPSS) over various time points. Key findings include 60% of patients being catheter-free by one month post-treatment and 83% recommending the procedure. The UroLift System is indicated for men with enlarged prostates and aims to provide rapid symptom relief without the adverse effects commonly associated with other treatments.

Teleflex Incorporated (NYSE: TFX) will release its second quarter 2020 financial results on July 30, 2020, before market open. An investor conference call is scheduled for the same day at 8:00 a.m. (ET), accessible via a live audio webcast on their website. A replay of the call will be available from 11:00 a.m. (ET) on July 30 to 11:00 a.m. (ET) on August 4, 2020. Teleflex specializes in medical technologies aimed at improving health and quality of life, with a diverse portfolio across various medical fields.

Teleflex announced survey results revealing that a significant number of American men over 40 are prescribed multiple medications, particularly for benign prostatic hyperplasia (BPH). The surveys showed that many believe BPH is solely medication-treatable, despite alternatives like the UroLift System being available. Over 54% of men with BPH use medication, with 27% having stopped due to side effects. The need for better patient education on minimally invasive treatments is emphasized, with over 175,000 men having opted for the UroLift System, a treatment that avoids common medication side effects.